As Baby Boomers age, the rate of Alzheimer’s disease will reach epic proportions. Unless new breakthrough treatments are developed soon, the consequences will be devastating for patients, families, and our healthcare system. Biopharmaceuticals are the best hope at stemming the tide of Alzheimer’s.

The U.S. is facing an epidemic that will devastate families and may bankrupt our healthcare system:

**ALZHEIMER’S DISEASE**

Today, more than 5 million patients live with Alzheimer’s, and that number is projected to grow to 13.5 million by 2050.

Patients and their families will experience extreme financial and emotional hardship.

The healthcare system will struggle to cope with cost.

**THE COMING WAVE:**

<table>
<thead>
<tr>
<th>Year</th>
<th>Medicaid + Medicare</th>
<th>Total Spending</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$154 Billion</td>
<td>$200 Billion</td>
</tr>
<tr>
<td>2050</td>
<td>$765 Billion</td>
<td>$1 Trillion</td>
</tr>
</tbody>
</table>

Patients and their families will be burdened out of pocket costs.

**PATIENTS AND THEIR FAMILIES WILL BE BURDENED**

2015: $44 Billion

2050: $198 Billion

OUT OF POCKET COSTS

bio.org
But what if we could stop the Alzheimer’s Tsunami? Our best hope at preventing this catastrophe is finding an effective medical treatment.

DRUGS HAVE A 3% APPROVAL RATE.

In the last 16 years, 123 medicines have been tested, 4 were approved.

If just ONE new treatment can delay the onset of Alzheimer’s by 5 years, the number of Alzheimer’s patients would drop by nearly one half, saving over $367 billion in healthcare costs.¹

¹ http://www.alz.org/documents_custom/trajectory.pdf